• Aprogen and related parties’ reported stake in Aprogen Biologics rose to 91.72% from 91.63% as of October 30, 2026.
• Holdings increased by 999,729 share equivalents following a convertible bond conversion-price adjustment on October 19, 2026.
• Their voting-share stake remained unchanged at 72.84%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030000609), on October 30, 2026, and is solely responsible for the information contained therein.